Blog
August 26, 2026
Making our models available in Claude, ChatGPT, and Benchling
.svg)
As part of OpenAI’s Rosalind Workbench launch today, we made our ADMET models available throughout the OpenAI ecosystem (including ChatGPT, Codex, and Rosalind Workbench). This is the latest in a series of integrations we’ve completed: In June, we made our models available in Claude as an ecosystem partner in the Claude Science launch; and earlier this month we made them available within Benchling as part of their ModelHub.
These models have placed 1st in three consecutive OpenADMET blind challenges across more than 750 competitors. We believe that drug discovery scientists deserve the best tools for chemical intelligence, regardless of what software stack they are using, and we’re excited to broaden access to our models.
Our thanks to our friends at Anthropic, OpenAI, and Benchling and for helpful collaboration throughout the process.
For all three integrations, we’ve made our global LogD and pKa models available free of charge. Fine-tuning global models usually improves performance. If you are interested in fine-tuning our models for your program, please reach out.
- QC analytical reports (1H/13C/19F/2D NMR, chiral SFC)
- Propose, visualize, and triage forward and retrosyntheses
- Monitor the synthesis queue and flag stalled targets
- QC assay data as it lands and flag suspicious results
- Prioritize repeats and nominate compounds for downstream assays
- Analyze SAR and identify data gaps
- Evaluate IVIVC and suggest diagnostic experiments
- Design, enumerate, and triage analogs
- Launch and analyze physics-based workflows like docking and FEP
- Project human PK and efficacious dose
- Answer questions about a program’s history (what was learned and when)
- Track team progress against the target candidate profile
- Get new scientists up to speed on a program
- Make meeting-ready slides and figures
Prompt: I’m attaching two files with activity data, one with new data from today and one with historical data. Can you look through the new data and identify any QC issues that I should be aware of? Create a csv where every compound + assay run pair is labeled with any relevant issues.
Prompt: Do a nitrogen walk around the core of this molecule: O=C(NCC1=CC=C(C)C(F)=C1)C2=CC=C3C=C(N4[C@H](C)CCCC4)C=CN32
Prompt: Do an OH walk around this whole molecule: O=C(NCC1=CC=C(C)C(F)=C1)C2=CC=C3C=C(N4[C@H](C)CCCC4)C=CN32
Prompt: Replace the core of this molecule with this set of 5,6-ring systems (file attached): O=C(NCC1=CC=C(C)C(F)=C1)C2=CC=C3C=C(N4[C@H](C)CCCC4)C=CN32
[Related posts]
September 17, 2026
Blog
Beacon-2: Completing the reward function for chemical optimization in drug discovery
Dose is the primary reward function of pre-clinical discovery, and we believe that making it computable via Beacon-2 is a step change for AI in drug discovery. Now, instead of optimizing individual properties in isolation, agentic systems can drive the drug discovery process itself.
September 14, 2026
Blog
Meet Indy: an AI chemistry assistant designed by medicinal chemists to do medicinal chemistry
Indy, our medicinal chemistry assistant, supports drug discovery programs in improving the rigor of day-to-day analyses and decisions, by QC-ing assay data and monitoring the synthesis queue, to launching FEP, projecting human dose, and making meeting-ready SAR and synthesis slides.
August 1, 2024
Blog
Are local or global models better? Why not both?
A long-standing debate in cheminformatics is whether global property-prediction models perform better or worse than local QSAR models. We describe a result from our publication with Nested Therapeutics in which we show that the best of both worlds is to train a model on global data and then fine-tune it on local data.
June 7, 2024
Blog
Approaching AlphaFold 3 docking accuracy in 100 lines of code
AlphaFold 3 (AF3) is an exciting leap forward in our ability to predict the structure and properties of biomolecular systems. We explore how AF3 small-molecule docking compares to existing techniques and find that the story is more nuanced than headlines suggest. We conclude with thoughts on where AF3 may ultimately be most useful.
November 20, 2023
Blog
Get with the program: building ADME datasets that drive impact
Research advances often don't translate to practical impact. In ML for small molecule drug discovery, this is at least partly because benchmark datasets don't capture important components of drug programs. We show how this can happen in ADME prediction and provide a path forward for building more realistic benchmarks from existing public data.